Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview (1)
- Neuropathology of neurodegeneration
- Assessing atrophy: determination of regional volumes
- Map of severity of atrophy
- Assessment of cellular changes
- Neuropathology of Ageing
- Age-associated accumulation of AD-type pathology
- Overview (2)
- AD: macroscopic pathology
- Regional atrophy in AD
- AD: Microscopic features
- A-beta (Aβ) plaques
- Neurofibrillary tangles (NFTs)
- Spread of Neurofibrillary tangles
- Evaluation of NFTs (Braak stage)
- Evaluation of neuritic plaques
- National Institute of Aging-Alzheimer’s Association Criteria for AD
- Neuron loss in AD
- Cholinergic neuron loss in AD
- Overview (3)
- Frontotemporal lobar degeneration
- Macroscopic findings
- Regional atrophy in FTLD
- FTLD: disease staging
- FTLD-tau: distribution by stage
- Microscopic pathology in FTLD – TDP-43
- Microscopic pathology in FTLD – tau
- FTLD – pathological classification
- Clinicopathological correlations
- Overview (4)
- Motor Neuron Disease
- ALS: microscopic pathology
- ALS: disease spread and staging
- Overlap: ALS and FTLD-TDP
- TDP staging – ALS and FTLD
- Overview (5)
- Lewy body diseases
- Regional atrophy in DLB
- LBD: neuropathological diagnosis
- DLB: other pathology
- Spread of Lewy bodies - Braak Staging
- Acknowledgments
- References
Topics Covered
- Pathologies seen in neurodegenerative disorders
- Alzheimer’s disease
- Frontotemporal dementia
- Amyotrophic lateral sclerosis and Lewy body diseases
- The macroscopic and microscopic features
- The nature and topography of protein deposits
- The pattern and extent of atrophy in neurodegenerative disorders
Talk Citation
Kril, J. (2021, June 29). Neuropathology of neurodegenerative disorders [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/RAWJ5806.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jillian Kril has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Neuroscience
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Jillian Kril,
I'm a professor of neuropathology at the University of Sydney, and
this presentation is on the neuropathology of neurodegenerative disorders.
I will describe the major pathological features of common groups of neurodegenerative diseases.
0:19
I will focus on the four main groups of
disorders that are commonly encountered in clinical practice.
These are Alzheimer's disease (AD), frontotemporal dementias (FTD),
motor neurone disease (MND/ALS), and Lewy Body diseases (LBD).
However, as these terms are often used to describe
both the clinical and the pathological entity,
I will endeavor to use 'Alzheimer's disease neuropathological change'
instead of 'Alzheimer's disease', and 'frontotemporal lobar degeneration'
instead of 'frontotemporal dementia'.
Unfortunately, there aren't different terms used for
the pathology and clinical presentations of ALS or Lewy body diseases.
1:01
In discussing each of these neuropathological disorders,
I will focus on the macroscopic features of the disease, the extent, severity,
and anatomical distribution of atrophy in particular.
This is because atrophy can be paralleled in neuroimaging, and
therefore the information that we glean from
neuropathological studies can be used to inform clinical diagnoses.
I will also look at the microscopic features,
in particular the proteinopathies that differentiate
these neurodegenerative disorders, and their cellular and anatomical distribution.
I will also examine the neuropathological diagnostic criteria for each disorder.